Randall Michael Giuffre bought $35k of DMAC
director at DiaMedica Therapeutics Inc.. 24,874 shares at an average of $1.40, traded Dec 6, 2022, filed Dec 8, 2022.
Score components
- +15RoleDirector
- +6Trade size$35k at market
- +3Relative to holdingsHoldings up 14%
- +8Price context64% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001235802-22-000134, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 6, 2022 | POpen-market purchase Voting Common Shares, no par value per share | +2,300 | $1.35 | $3,105 | 180,572 | Dec 8, 2022 |
| Dec 7, 2022 | POpen-market purchase Voting Common Shares, no par value per share | +22,574 | $1.40 | $32k | 203,146 | Dec 8, 2022 |
Related signals
Other insiders at DiaMedica Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | DMACbuy DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $7.6M 1,061,277 shares | +14% | |
| 40Moderate | DMACbuy DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $6.0M 1,000,000 shares | +15% | |
| 57Moderate | DiaMedica Therapeutics Inc. | Thomas Von Koch owner | $10.0M 2,857,142 shares | +52% | |
| 53Moderate | DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $5.4M 1,542,857 shares | +30% | |
| 50Moderate | DiaMedica Therapeutics Inc. | Richard Jacinto II owner | $1.4M 400,000 shares | +9% | |
| 64Notable | DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $3.0M 1,200,000 shares | +30% | |
| 54Moderate | DiaMedica Therapeutics Inc. | Thomas Von Koch owner | $3.0M 1,200,000 shares | +28% | |
| 30Weak | DMACbuy DiaMedica Therapeutics Inc. | David J. Wambeke Chief Business Officer | $49k 20,000 shares | +4% | |
| 58Moderate | DiaMedica Therapeutics Inc. | Randall Michael Giuffre director | $81k 57,079 shares | +28% | |
| 63Notable | DiaMedica Therapeutics Inc. | Thomas Von Koch owner | $3.5M 2,855,847 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.